U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH HALOZYME'S ENHANZE® TECHNOLOGY FOR THE TREATMENT OF ADVANCED HEAD AND NECK CANCER

Reuters · 2d ago

Please log in to view news